XML 21 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Revenues:        
Revenue under collaborative research and development arrangements $ 2,327,316 $ 16,475,083 $ 6,014,161 $ 25,055,890
Revenue under collaborative research and development arrangements with affiliated entity 574,596 125,000 1,211,316 404,167
Grants and miscellaneous revenue 9,410,648 7,583,151 19,401,029 9,176,492
Grants and miscellaneous revenue from affiliated entity 227,903 0 227,903 0
Total revenues 12,540,463 24,183,234 26,854,409 34,636,549
Operating expenses:        
Research and development 26,980,343 16,075,201 64,800,304 42,190,032
General and administrative 5,755,603 4,377,616 16,926,746 13,203,804
Gain on sale of assets 0 0 (1,000,000) (1,000,000)
Total operating expenses 32,735,946 20,452,817 80,727,050 54,393,836
Income (Loss) from operations (20,195,483) 3,730,417 (53,872,641) (19,757,287)
Other income (expense):        
Interest and other income, net 391,596 214,982 1,065,797 499,590
Change in fair value of common stock warrants, net 2,690 518,877 (517,334) 467,877
Gain (loss) on investment in affiliated entity (958,141) (659,054) 5,817,309 5,849,782
Net income (loss) before income tax benefit (20,759,338) 3,805,222 (47,506,869) (12,940,038)
Income tax benefit 0 1,789,246 0 1,789,246
Net income (loss) (20,759,338) 5,594,468 (47,506,869) (11,150,792)
Net (income) loss attributable to non-controlling interest 0 0 0 (84,769)
Net income (loss) attributable to Inovio Pharmaceuticals, Inc. $ (20,759,338) $ 5,594,468 $ (47,506,869) $ (11,235,561)
Net income (loss) per common share attributable to Inovio Pharmaceuticals, Inc. stockholders:        
Basic (in USD per share) $ (0.28) $ 0.08 $ (0.65) $ (0.17)
Diluted (in USD per share) $ (0.28) $ 0.07 $ (0.65) $ (0.18)
Weighted average number of common shares outstanding used in per share calculations:        
Basic (in shares) 73,602,834 72,029,644 72,932,199 66,846,481
Diluted (in shares) 73,789,008 73,961,237 72,932,199 67,018,961